StreetAlpha.app
Home › Stocks › INSM

INSMED Inc (INSM)

Healthcare
$141.33
▼ −2.17%
LAST CLOSE · NOV 20

INSMED develops and sells medicines for serious lung diseases and other conditions, based in Bridgewater, New Jersey. It last closed at $141.33 on Nov 20, down 2.17% on the day. The next earnings report for INSM is expected around Thu, Feb 18, 2027. For the quarter ended Sep 2026, INSM reported EPS of -$0.46 on revenue of $524.4M, with revenue up 268.4% from a year ago. Over its last 8 reports the stock moved an average of 12.6% the session after earnings. Over the last 12 months INSM insiders bought $0 of stock on the open market and sold $148.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is INSM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold INSM.

Key Stats

Last 12 months
Results
Revenue
$1.5B
+240.0% vs a year ago
Net income
−$605.6M
−39.9% margin
EPS (diluted)
−$2.81
Free cash flow
−$627.6M
−41.3% margin
Valuation
Market cap
$31.0B
219.4M shares
P/E
–
No P/E while losing money
Price to sales
20.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$396.6M
At Sep 30
Debt
$546.8M
At Sep 30
Shareholder equity
$726.2M
Shares outstanding
219.4M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $188.5M$188.5MFY2021FY2022: $245.4M$245.4MFY2022FY2023: $305.2M$305.2MFY2023FY2024: $363.7M$363.7MFY2024FY2025: $606.4M$606.4MFY2025

From INSM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 18
Estimated date · Time not announced
Reported EPS
-$0.46
Quarter ended Sep 2026
Year ago EPS
-$1.75
Same quarter last year
Revenue
$524.4M
+268.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.30Dec '24Mar 2025: -$1.42Mar '25Jun 2025: -$1.70Jun '25Sep 2025: -$1.75Sep '25Dec 2025: -$1.53Dec '25Mar 2026: -$0.76Mar '26Jun 2026: -$0.06Jun '26Sep 2026: -$0.46Sep '26Latest -$0.46
Revenue by quarter
Dec 2024: $104.4MDec '24Mar 2025: $92.8MMar '25Jun 2025: $107.4MJun '25Sep 2025: $142.3MSep '25Dec 2025: $263.8MDec '25Mar 2026: $306.0MMar '26Jun 2026: $425.5MJun '26Sep 2026: $524.4MSep '26Latest $524.4M
How INSM moved after its last 8 reports
Average move the session after a report ±12.6%
Oct 29, 2026Time not announced+15.1%
Aug 6, 2026Time not announced+33.9%
May 7, 2026Time not announced−23.4%
Feb 19, 2026Time not announced+6.5%
Oct 30, 2025Time not announced+16.3%
Aug 7, 2025Time not announced−1.8%
May 8, 2025Time not announced−3.9%
Feb 20, 2025Time not announced−0.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on INSMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on INSM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on INSM

Technical Analysis

INSM · as of the Nov 20 close · updated each morning
Turning up, overbought

The stock is 19% above its 20 day and 21% above its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 73), overbought. The nearest support is the Pivot S1 at $138.21, and the nearest resistance the Pivot at $144.11.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchOverbought
VolatilityHigh, 4.8%/day
Key levels
$212.7552 week high+50.5%
$147.22Pivot R1+4.2%
$144.11Pivot+2.0%
$141.33Last close
$138.21Pivot S1−2.2%
$122.56200 day average−13.3%
$122.21Swing low (Aug 14)−13.5%
$115.1120 day average−18.6%
$114.28100 day average−19.1%
$111.0950 day average−21.4%
$90.3952 week low−36.0%
Indicators
RSI (14)73.20Overbought above 70Overbought
MACD7.42Above its signal lineBullish
Stochastic82.9Near the top of its rangeOverbought
ADX (14)35.2Trending up
Williams %R-18.3Oversold below −80, overbought above −20Overbought
CCI (20)216.1Oversold below −100, overbought above 100Overbought
Rate of change+23.5%Change over 10 sessionsBullish
ATR (14)$6.79Typical daily range, 4.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for INSM

What happened before

See how INSM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow INSM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How INSM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for INSMHow many large options trades hit INSM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

INSM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲399 buying vs 309 selling
  • ▼Held by funds -1.9 pts
  • ▲Funds holding +36
  • ▼Superinvestors: 1 added, 5 cut
  • ▼Put/call 0.29 to 0.37
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding707671+5.4%
In funds' top 101716+6.3%
Held by funds100.3%102.1%−1.9 pts
New / increased128 / 271114 / 247+10.5%
Reduced / sold out221 / 88231 / 122−12.5%
Put/call ratio0.370.29+25.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INSM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

INSM Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$148.4M55 sales · 9 insiders
66% of the selling was under pre-arranged trading plans.
2025-12 sold $9.9M2026-01 sold $29.4M2026-02 sold $9.8M2026-03 sold $6.1M2026-04 sold $17.8M2026-05 sold $11.9M2026-06 sold $4.9M2026-07 sold $3.7M2026-08 sold $36.1M2026-09 sold $3.1M2026-11 sold $14.7MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 19Orlov S Nicole SchaefferChief People Strategy OfficerSale plan101,100$145.26$14.7M
Sep 9David R BrennanDirectorSale25,000$124.00$3.1M
Aug 17Melvin Sharoky MdDirectorSale5,000$127.53$638K
Aug 10Roger AdsettCOOSale239,850$133.27$32.0M
Aug 6Martina M.D. FlammerChief Medical OfficerSale plan27,173$128.61$3.5M
Jul 23William LewisChair and CEOSale plan10,700$106.06$1.1M
Every insider buy and sale for INSM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See INSM insider trades →

From SEC Form 4 filings by INSM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INSM is in one of them and how their past INSM trades turned out.

INSM in the AI portfolios
Loading…

INSM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INSM in an article yet. Here's the latest on the wider market.

INSM in the news

INSM Congress Trades

All congress trades →
Trades, 12 months
1
Buys
0
0%
Sells
1
100%
People
1
Last filed Jul 7
Who traded INSM · since 2022
Latest 5 filings of 10
Josh GottheimerSell (partial)
$1K – $15KTraded Jun 10, 2026Filed Jul 7, 2026
$1K – $15KTraded Oct 3, 2025Filed Nov 18, 2025
Gilbert CisnerosSell (partial)
$1K – $15KTraded Sep 22, 2025Filed Oct 10, 2025
Gilbert CisnerosSell (partial)
$1K – $15KTraded Aug 8, 2025Filed Sep 12, 2025
Gilbert CisnerosSell (partial)
$1K – $15KTraded Jul 7, 2025Filed Aug 14, 2025
PersonTypeAmountTradedFiledDelay
Josh GottheimerD · NJSell (partial)$1K – $15KJun 10, 2026Jul 7, 202627 d
Gilbert CisnerosD · CASell$1K – $15KOct 3, 2025Nov 18, 202546 d
Gilbert CisnerosD · CASell (partial)$1K – $15KSep 22, 2025Oct 10, 202518 d
Gilbert CisnerosD · CASell (partial)$1K – $15KAug 8, 2025Sep 12, 202535 d
Gilbert CisnerosD · CASell (partial)$1K – $15KJul 7, 2025Aug 14, 202538 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About INSMED

INSMED is a biopharmaceutical company based in Bridgewater, New Jersey. It develops and sells medicines for serious diseases, with a focus on lung conditions. Its two marketed products are ARIKAYCE, an inhaled treatment for lung disease caused by MAC, and BRINSUPRI, an oral tablet for bronchiectasis, a chronic lung disease. Its other programs target pulmonary hypertension, an immune condition called hidradenitis suppurativa, and neurological diseases such as Duchenne muscular dystrophy and ALS. Its patients are people living with these conditions.

Headquarters
Bridgewater, NJ